Evidence map›Paper›PMID 25208761›Full record

ArticleNature communications2014

Spatial control of Cdc42 signalling by a GM130-RasGRF complex regulates polarity and tumorigenesis.

Francesco Baschieri, Stefano Confalonieri, Giovanni Bertalot, Pier Paolo Di Fiore, Wolfgang Dietmaier, Marcel Leist, Piero Crespo, Ian G Macara, Hesso Farhan

Open access · bronzeAbstract read
In one paragraph

Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 98 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Inborn Errors of Immunity and Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. A distinct Golgi-targeting mechanism of dGM130 inFrontiers in molecular neuroscience · 2023
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Molecular subversion of Cdc42 signalling in cancer.Biochemical Society transactions · 2021
    Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Francesco Baschieri1] University of Konstanz, 78464 Konstanz, Germany [2] Biotechnology Institute Thurgau, University of Konstanz, Kreuzlingen CH-8280, Switzerland.
Stefano Confalonieri1] Molecular Medicine for Care Program, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy [2] IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.
Giovanni BertalotMolecular Medicine for Care Program, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
Pier Paolo Di Fiore1] Molecular Medicine for Care Program, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy [2] IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy [3] Dipartimento di Scienze della Salute, Università degli Studi di Milano, Via Antonio di Rudinì 8, 20142 Milan, Italy.
Wolfgang DietmaierUniversity of Regensburg, Institute of Pathology and molecular diagnostics, 93053 Regensbur, Germany.
Marcel LeistUniversity of Konstanz, 78464 Konstanz, Germany.
Piero CrespoInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria-SODERCAN. 39005 Santander, Spain.
Ian G MacaraDepartment of Cell &Developmental Biology, Vanderbilt University, Nashville, Tennessee 37235, USA.
Hesso Farhan1] University of Konstanz, 78464 Konstanz, Germany [2] Biotechnology Institute Thurgau, University of Konstanz, Kreuzlingen CH-8280, Switzerland.
European Institute of Oncology · ITUniversity of Konstanz · DEConsejo Superior de Investigaciones Científicas · ESUniversity of Regensburg · DEVanderbilt University · US

Funding

MECHANISMS OF CELL POLARITY ESTABLISHMENTR01GM070902 · NIGMS · VANDERBILT UNIVERSITY · PI MACARA, IAN G · 2004 to 2022
$5.4M
NIGMS NIH HHS R01 GM070902
6 · The paper itself

Abstract

The small GTPase Cdc42 is a key regulator of polarity, but little is known in mammals about its spatial regulation and the relevance of spatial Cdc42 pools for polarity. Here we report the identification of a GM130-RasGRF complex as a regulator of Cdc42 at the Golgi. Silencing GM130 results in RasGRF-dependent inhibition of the Golgi pool of Cdc42, but does not affect Cdc42 at the cell surface. Furthermore, active Cdc42 at the Golgi is important to sustain asymmetric front-rear Cdc42-GTP distribution in directionally migrating cells. Concurrent to Cdc42 inhibition, silencing GM130 also results in RasGRF-dependent Ras-ERK pathway activation. Moreover, depletion of GM130 is sufficient to induce E-cadherin downregulation, indicative of a loss in cell polarity and epithelial identity. Accordingly, GM130 expression is frequently lost in colorectal and breast cancer patients. These findings establish a previously unrecognized role for a GM130-RasGRF-Cdc42 connection in regulating polarity and tumorigenesis.

Indexed as

Antigens, CDAutoantigensCadherinsCarcinogenesiscdc42 GTP-Binding ProteinCell Line, TumorCell PolarityGene Expression Regulation, NeoplasticGene SilencingHumansMAP Kinase Signaling SystemMCF-7 CellsMembrane ProteinsMitogen-Activated Protein Kinase 3ras-GRF1ras Guanine Nucleotide Exchange FactorsAntigens, CDAutoantigensCadherinscdc42 GTP-Binding ProteinCDH1 protein, humanGolgin subfamily A member 2Membrane ProteinsMitogen-Activated Protein Kinase 3ras-GRF1RASGRF1 protein, humanRASGRF2 protein, humanras Guanine Nucleotide Exchange FactorsRho Guanine Nucleotide Exchange Factors

Identifiers

PMID25208761
PMCPMC4449154
OpenAlexW2006835596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.